Published in J Clin Oncol on February 01, 1998
Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood (2006) 2.62
Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol (2008) 2.04
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol (2010) 1.52
Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol (2012) 1.32
Early detection of doxorubicin cardiomyopathy using two-dimensional strain echocardiography. Ultrasound Med Biol (2007) 1.30
Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer (2004) 1.29
Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421. J Clin Oncol (2008) 1.15
Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood. J Cancer Surviv (2011) 0.97
Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. Future Cardiol (2012) 0.91
Cardiac damage after treatment of childhood cancer: a long-term follow-up. BMC Cancer (2008) 0.90
Review of cardiotoxicity in pediatric cancer patients: during and after therapy. Cardiol Res Pract (2011) 0.88
Cardiovascular disease in adult survivors of childhood cancer. Annu Rev Med (2015) 0.87
Cardiovascular effects in childhood cancer survivors treated with anthracyclines. Cardiol Res Pract (2011) 0.86
Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes. Pediatrics (2012) 0.86
Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicity. Cancer Res Treat (2008) 0.83
Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature Review. Cardiovasc Toxicol (2016) 0.82
Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors. J Korean Med Sci (2010) 0.81
Cardiomyopathy Caused by Antineoplastic Therapies. Curr Treat Options Cardiovasc Med (2001) 0.79
Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors. Cancer (2016) 0.79
Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond. Can J Cardiol (2016) 0.75
Topics in pediatric leukemia--acute lymphoblastic leukemia and late effects in long-term survivors. MedGenMed (2005) 0.75
Late cardiomyopathy in childhood acute myeloid leukemia survivors: a study from the L.E.A. program. Haematologica (2015) 0.75
Endocrinological and cardiological late effects among survivors of childhood acute lymphoblastic leukemia. Turk J Haematol (2013) 0.75
Cardiac functional evaluation using vector velocity imaging after chemotherapy including anthracyclines in children with cancer. Korean Circ J (2009) 0.75
Cardiac function in long-term survivors of childhood lymphoma. Cardiol Res Pract (2011) 0.75
Combination of dexamethasone, high-dose cytarabine, and carboplatin is effective for advanced large-cell non-Hodgkin lymphoma of childhood. Cancer (2008) 0.75
Administration of Dexrazoxane Improves Cardiac Indices in Children and Young Adults With Acute Myeloid Leukemia (AML) While Maintaining Survival Outcomes. J Pediatr Hematol Oncol (2017) 0.75
The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull (1999) 14.29
Incidence and types of adverse events and negligent care in Utah and Colorado. Med Care (2000) 13.46
A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med (1991) 5.76
Impact of language barriers on patient satisfaction in an emergency department. J Gen Intern Med (1999) 5.35
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med (1991) 5.22
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol (1996) 5.09
Using a computerized sign-out program to improve continuity of inpatient care and prevent adverse events. Jt Comm J Qual Improv (1998) 4.92
Hospital characteristics associated with adverse events and substandard care. JAMA (1991) 4.77
Prognosis of cancers associated with venous thromboembolism. N Engl J Med (2000) 4.51
Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA (1997) 4.49
The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med (1998) 4.41
Quality of life and clinical outcomes in elderly patients treated with ventricular pacing as compared with dual-chamber pacing. Pacemaker Selection in the Elderly Investigators. N Engl J Med (1998) 4.22
Monitoring for anthracycline cardiotoxicity. Pediatrics (1994) 4.05
Induced abortion and the risk of breast cancer. N Engl J Med (1997) 4.04
Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med (1995) 4.03
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood (2001) 3.93
Do the poor sue more? A case-control study of malpractice claims and socioeconomic status. JAMA (1993) 3.73
Causes of death in homeless adults in Boston. Ann Intern Med (1997) 3.71
Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst (1997) 3.57
Socioeconomic status and risk for substandard medical care. JAMA (1992) 3.50
A pooled analysis of magnetic fields and childhood leukaemia. Br J Cancer (2000) 3.49
Effects of oral administration of type II collagen on rheumatoid arthritis. Science (1993) 3.32
Risk for subsequent cancer after diagnosis of basal-cell carcinoma. A population-based, epidemiologic study. Ann Intern Med (1996) 3.18
Monte Carlo EM for missing covariates in parametric regression models. Biometrics (1999) 3.17
Development of homozygosity for chromosome 11p markers in Wilms' tumour. Nature (1984) 2.97
Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science (1993) 2.97
Cloning and characterization of two mouse heat shock factors with distinct inducible and constitutive DNA-binding ability. Genes Dev (1991) 2.95
The efficacy of preemployment drug screening for marijuana and cocaine in predicting employment outcome. JAMA (1990) 2.89
Serological markers and HLA genes among healthy first-degree relatives of patients with coeliac disease. Lancet (1991) 2.76
Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med (1975) 2.71
The "To Err is Human" report and the patient safety literature. Qual Saf Health Care (2006) 2.67
Negligent care and malpractice claiming behavior in Utah and Colorado. Med Care (2000) 2.51
Determinants of patient satisfaction and willingness to return with emergency care. Ann Emerg Med (2000) 2.49
Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol (2001) 2.48
Practice guidelines and malpractice litigation: a two-way street. Ann Intern Med (1995) 2.48
Rheumatoid arthritis and cancer risk. Eur J Cancer (1996) 2.44
Deregulated expression of E2F family members induces S-phase entry and overcomes p16INK4A-mediated growth suppression. Mol Cell Biol (1996) 2.44
Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology (1995) 2.42
Appendectomy and subsequent risk of inflammatory bowel diseases. Surgery (2001) 2.35
Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler (1999) 2.35
Tolerance and specificity of polyketide synthases. Annu Rev Biochem (1999) 2.34
Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation (1997) 2.34
Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer (1994) 2.33
Prognostic significance of clinically silent coronary artery fistulas. Am J Cardiol (1999) 2.29
Two-dimensional echocardiographic findings in double orifice mitral valve. J Am Coll Cardiol (1985) 2.23
Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology (1998) 2.19
Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol (2000) 2.18
Cardiotoxicity during treatment of severe childhood asthma. Pediatrics (1991) 2.14
Risk factors for death in homeless adults in Boston. Arch Intern Med (1998) 2.13
Parameter estimation from incomplete data in binomial regression when the missing data mechanism is nonignorable. Biometrics (1996) 2.12
Performance of generalized estimating equations in practical situations. Biometrics (1994) 2.12
E2F-6: a novel member of the E2F family is an inhibitor of E2F-dependent transcription. Oncogene (1998) 2.12
The relationship of postoperative delirium with psychoactive medications. JAMA (1994) 2.09
Malignant tumours and psoriasis: climatotherapy at the Dead Sea. Br J Dermatol (1999) 2.06
Cardiac dysfunction and mortality in HIV-infected children: The Prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation (2000) 2.04
Supraventricular arrhythmia in patients having noncardiac surgery: clinical correlates and effect on length of stay. Ann Intern Med (1998) 2.04
Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol (1997) 2.02
Does the computerized display of charges affect inpatient ancillary test utilization? Arch Intern Med (1997) 2.01
Outcome of pregnancy in survivors of Wilms' tumor. JAMA (1987) 2.00
Central nervous system disease in childhood acute lymphoblastic leukemia: prognostic factors and results of treatment. Pediatr Hematol Oncol (1992) 1.99
Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia (2009) 1.99
Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol (1997) 1.98
Evaluation of regional differences in right ventricular systolic function by acoustic quantification echocardiography and cine magnetic resonance imaging. Circulation (1998) 1.98
The association of physician attitudes about uncertainty and risk taking with resource use in a Medicare HMO. Med Decis Making (1998) 1.93
Improved visual function and attenuation of declines in health-related quality of life after cataract extraction. Arch Ophthalmol (1994) 1.93
Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. J Pediatr Hematol Oncol (2000) 1.93
The association of intraoperative factors with the development of postoperative delirium. Am J Med (1998) 1.92
Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. N Engl J Med (1992) 1.92
A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer (2003) 1.88
Risk of cancer among offspring of childhood-cancer survivors. Association of the Nordic Cancer Registries and the Nordic Society of Paediatric Haematology and Oncology. N Engl J Med (1998) 1.87
Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med (2000) 1.87
Influence of age-related maculopathy on visual functioning and health-related quality of life. Am J Ophthalmol (1999) 1.86
Autoimmune disease and risk for Parkinson disease: a population-based case-control study. Neurology (2009) 1.86
Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr (1998) 1.84
Non-neoplastic mortality of European workers who produce man made vitreous fibres. Occup Environ Med (1999) 1.83
Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer (1997) 1.82
Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology (1993) 1.81
Goodness-of-fit for GEE: an example with mental health service utilization. Stat Med (1999) 1.81
Evolution of risk factors influencing early mortality of the arterial switch operation. J Am Coll Cardiol (1999) 1.80
Increase in gamma/delta T cell receptor bearing lymphocytes in normal small bowel mucosa in latent coeliac disease. Gut (1991) 1.80
Air pollution from traffic at the residence of children with cancer. Am J Epidemiol (2001) 1.79
Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med (1980) 1.78
Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood (1981) 1.77
Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology (1989) 1.77
Normal small bowel biopsy followed by coeliac disease. Arch Dis Child (1990) 1.74
Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin Exp Immunol (2002) 1.74
Risk of testicular cancer in men with abnormal semen characteristics: cohort study. BMJ (2000) 1.73